arrow
N

Nicolas Folschweiller

takeda pharmaceuticals international ag
H指数:18
被引数:1,144

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Corrigendum to “Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine” [Vaccine 62 (2025) 127558]

勘误: “活减毒四价登革热疫苗(TAK-003)与重组九价人乳头瘤病毒疫苗联合接种的免疫原性和安全性” [Vaccine 62 (2025) 127558]

Vaccine
IF3.5
2025-10-080
PRE
Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine

四价减毒活登革热疫苗(TAK-003)与重组九价人乳头瘤病毒疫苗同时接种时的免疫原性和安全性

Vaccine
IF3.5
2025-10-060
OAAI
Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine

四价减毒活登革热疫苗(TAK-003)与重组九价人乳头瘤病毒疫苗联合接种的免疫原性和安全性

Vaccine
IF3.5
2025-07-310
OA
Estimated Efficacy of TAK-003 Against Asymptomatic Dengue Infection in Children and Adolescents Participating in the DEN-301 Trial in Asia Pacific and Latin America

亚洲太平洋和拉丁美洲地区参与DEN-301试验的儿童和青少年中,TAK-003对无症状登革热感染的预估疗效

2025-03-181
PRE
Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination
2024-04-294
OAAI
Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial
2022-07-0114
OAAI
Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study
2020-09-059
OAAI
Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15-25 years: A phase IV randomized comparative study
2020-06-0110
OAAI
Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials
2019-11-0723
OAAI
Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2-or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine

在AS04-Adjuvanted人乳头瘤病毒/18疫苗的2或3剂量方案后,对非疫苗人HPV-16病毒31型和45型的长期交叉反应性

2019-02-0313
OAAI
Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized Trial
2017-06-0730
OAAI
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2-and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial

人乳头瘤病毒 (HPV) 16/18 AS04-adjuvanted疫苗和HPV-6/11/16/18疫苗的比较免疫原性和安全性根据9-14岁女孩的2剂量和3剂量时间表: 从随机试验到第12个月的结果

2015-06-1042
OAAI